Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11669798 | 1.00 | GAA (0.46) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2535265 | 0.98 | SMN1; SMN2 (0.47) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL11554100 | 0.93 | ALDH1A1 (0.46) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL295263 | 0.89 | — | — | |
| SCHEMBL16879368 | 0.89 | SMN1; SMN2 (0.41) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15710144 | 0.85 | ALDH1A1 (0.43) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15709601 | 0.85 | ALDH1A1 (0.43) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15743173 | 0.85 | ALDH1A1 (0.43) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15709843 | 0.85 | ALDH1A1 (0.43) | GAAPOLBSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15725217 | 0.80 | SMN1; SMN2 (0.38) | GAAPOLBSMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | claimed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | claimed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | claimed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067515-A1 | THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-4007031-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-02-08 | — | — | US | disclosed |
| US-4004912-A | 1-Thiadiazolyl-6-acyloxytetrahydropyrimidinone herbicides | VELSICOL CHEMICAL CORPORATION (US) | 1977-01-25 | — | — | US | disclosed |
| US-3990882-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-11-09 | — | — | US | disclosed |
| US-3951640-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
| US-3944409-A | Method of increasing the yield of plants having storage organs by treatment with thiadiazolylimidazolines | VELSICOL CHEMICAL CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
| US-3933839-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
| US-3931209-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | GAA 4385/4885POLB 4152/4885SMN1; SMN2 4744/4885 |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | GAA 131/4885POLB 3697/4885SMN1; SMN2 47/4885 |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | APP, BACE1, PSEN1 | GAA 131/4885POLB 3697/4885SMN1; SMN2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.